Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 3

1(20.0%)

Early Phase 1

1(20.0%)

Phase 1

1(20.0%)

5Total

N/A(2)

Phase 3(1)

Early Phase 1(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05850546Phase 3Not Yet Recruiting

Rituximab in the First Episode of Paediatric Nephrotic Syndrome

Role: collaborator

NCT06685497Not ApplicableNot Yet Recruiting

COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer

Role: collaborator

NCT04706598Phase 1Active Not Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Role: collaborator

NCT04700345Not ApplicableUnknown

Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Role: collaborator

NCT04853082Early Phase 1Completed

Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution

Role: collaborator

NCT02940977Unknown

Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique

Role: collaborator

NCT02951169Unknown

Exploration of Standard Surgical Indication in Gallbladder Benign Disease

Role: collaborator

All 7 trials loaded